A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-39053-6_3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• An FDA oncology analysis of antibody-drug conjugates.

  2015cited by this paper
• The return of the prodigal son and the extraordinary development route of antibody TGN1412 ‐ lessons for drug development and clinical pharmacology

  2015cited by this paper
• Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

  2014cited by this paper
• Estimating the “First in human” dose – a revisit with particular emphasis on oncology drugs

  2013cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation

  2012cited by this paper
• Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

  2012cited by this paper
• Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

  2011cited by this paper
• On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

  2010cited by this paper
• Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

  2010cited by this paper
• Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.

  2010cited by this paper
• Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.

  2010cited by this paper
• Information Needed to Conduct First-in-Human Oncology Trials in the United States: A View from a Former FDA Medical Reviewer

  2010cited by this paper
• Targeted cancer therapies

  2010cited by this paper
• Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.

  2010cited by this paper
• Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.

  2009cited by this paper
• Safety Assessment and Dose Selection for First‐in‐Human Clinical Trials With Immunomodulatory Monoclonal Antibodies

  2009cited by this paper
• On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

  2007cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Multi-species toxicology approaches for oncology drugs: the US perspective.

  2004cited by this paper
• Mouse and large-animal toxicology studies of twelve antitumor agents: Relevance to starting dose for Phase I clinical trials

  2004cited by this paper
• First dose of potential new medicines to humans: how animals help

  2004cited by this paper
• Estimating the starting dose for entry into humans: principles and practice

  2002cited by this paper
• Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers.

  1998cited by this paper
• Pharmacologically guided phase I clinical trials based upon preclinical drug development.

  1990cited by this paper
• Animal toxicology for early clinical trials with anticancer agents.

  1981cited by this paper

• Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment

  2025cites this paper
• Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs

  2020cites this paper